title: Regionally Specific Brain Volumetric and Cortical Thickness Changes in HIV-Infected Patients in the HAART Era.
abstract: Cognitive impairment still occurs in a substantial subset of HIV-infected patients, despite effective viral suppression with highly active antiretroviral therapy (HAART). Structural brain changes may provide clues about the underlying pathophysiology. This study provides a detailed spatial characterization of the pattern and extent of brain volume changes associated with HIV and relates these brain measures to cognitive ability and clinical variables.
  
  
  
  Multiple novel neuroimaging techniques (deformation-based morphometry, voxel-based morphometry, and cortical modeling) were used to assess regional brain volumes in 125 HIV-infected patients and 62 HIV-uninfected individuals. Ninety percent of the HIV-infected patients were on stable HAART with most of them (75%) having plasma viral suppression. Brain volumetrics and cortical thickness estimates were compared between the HIV-infected and uninfected groups, and the relationships between these measures of brain volume and indices of current and past infection severity, central nervous system penetration of HAART, and cognitive performance were assessed.
  
  
  
  Regionally specific patterns of reduced thalamic and brainstem volumes and reduced cortical thickness in the orbitofrontal cortex, cingulate gyrus, primary motor and sensory cortex, temporal, and frontal lobes were seen in HIV-infected patients compared to HIV-uninfected participants. Observed white matter loss and subcortical atrophy were associated with lower nadir CD4 cell counts, while reduction in cortical thickness was related to worse cognitive performance.
  
  
  
  Our findings suggest that distinct mechanisms may underlie cortical and subcortical injury in people with HIV and argues for the potential importance of early initiation of HAART to protect long-term brain health.
authors.affiliation: *Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada; †Division of Clinical Epidemiology, McGill University, Montreal, Quebec, Canada; and ‡Department of Neurology, Washington University, St. Louis, Missouri.
authors.forename: Ryan
authors.initials: R
authors.lastname: Sanford
authors.forename: Ana Lucia
authors.initials: AL
authors.lastname: Fernandez Cruz
authors.forename: Susan C
authors.initials: SC
authors.lastname: Scott
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Mayo
authors.forename: Lesley K
authors.initials: LK
authors.lastname: Fellows
authors.forename: Beau M
authors.initials: BM
authors.lastname: Ances
authors.forename: D Louis
authors.initials: DL
authors.lastname: Collins
mesh_terms: D015526:AIDS Dementia Complex / Q000000981:diagnostic imaging / Q000473:pathology*; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D001699:Biometry; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology*; D003071:Cognition; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D059906:Neuroimaging; D009483:Neuropsychological Tests
chemical_list: D044966:Anti-Retroviral Agents